0 results available. Select is focused ,type to refine list, press Down to open the menu,
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and int...
The following section summarizes insights on Glaukos Corp's Net Income to Common Excl Extra Items:
We've identified the following companies as similar to Glaukos Corp because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
| Name | Ticker | Net Income to Common Excl Extra Items |
|---|---|---|
| Koninklijke Philips NV ADR | NYSE:PHG | -874.3 M |
| Glaukos Corp | NYSE:GKOS | -146.4 M |
| CVRx Inc | NASDAQGS:CVRX | -59.965 M |
| Paragon 28 Inc | NYSE:FNA | -54.639 M |
| Sight Sciences Inc | NASDAQGS:SGHT | -51.507 M |
| Orthopediatrics Corp | NASDAQGM:KIDS | -37.822 M |
| Healthcare | SECTOR:HLTH.US | -19.21 M |
| Nova Eye Medical Limited | OTCPK:ELXM.F | -5.297 M |
| QT Imaging Holdings Inc | OTCPK:QTIH | -3.799 M |
| REMSleep Holdings Inc | OTCPK:RMSL | -1.814 M |
| DexCom Inc | NASDAQGS:DXCM | 576.2 M |
| Alcon AG | NYSE:ALC | 1.018 B |
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Net Income to Common Excl Extra Items in the financials category include:
Represents the net income or loss available to common stockholders and is arrived after adjusting preferred stock dividends and other adjustments to n...
Glaukos reported net income to common excl extra items of -146.4 M for the latest twelve months ending December 31, 2024 on its income statement.
The tables below summarizes Glaukos’s Net Income to Common Excl Extra Items and common size over the last five years:
| Fiscal Year | Net Income to Common Excl Extra Items | Revenue | % Revenue |
|---|---|---|---|
| 2020-12-31 | -120.3 M | 225 M | −53.5% |
| 2021-12-31 | -49.593 M | 294 M | −16.9% |
| 2022-12-31 | -99.195 M | 282.9 M | −35.1% |
| 2023-12-31 | -134.7 M | 314.7 M | −42.8% |
| 2024-12-31 | -146.4 M | 383.5 M | −38.2% |
The tables below summarizes Glaukos’s Net Income to Common Excl Extra Items and common size over the last four quarters:
| Quarter Ending | Net Income to Common Excl Extra Items | Revenue | % Revenue |
|---|---|---|---|
| 2024-03-31 | -40.838 M | 85.622 M | −47.7% |
| 2024-06-30 | -50.545 M | 95.69 M | −52.8% |
| 2024-09-30 | -21.409 M | 96.67 M | −22.1% |
| 2024-12-31 | -33.58 M | 105.5 M | −31.8% |
The chart above depicts the distribution of net income to common excl extra items for companies operating in the Healthcare sector in the Developed economic region. Over 2,495 companies were considered in this analysis, and 2,400 had meaningful values. The average net income to common excl extra items of companies in the sector is -829.785 K with a standard deviation of 148.4 M.
Glaukos Corp's Net Income to Common Excl Extra Items of -146.4 M ranks in the 6.3% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,500 |
| Included Constituents | 2,400 |
| Min | -372.2 M |
| Max | 1.322 B |
| Median | -5.393 M |
| Mean | -829.785 K |
| Standard Deviation | 148.4 M |
You can find companies with similar net income to common excl extra items using this stock screener.